Cellular and Molecular Life Sciences

, Volume 76, Issue 2, pp 259–281 | Cite as

The master regulator FUBP1: its emerging role in normal cell function and malignant development

  • Lydie Debaize
  • Marie-Bérengère TroadecEmail author


The human Far Upstream Element (FUSE) Binding Protein 1 (FUBP1) is a multifunctional DNA- and RNA-binding protein involved in diverse cellular processes. FUBP1 is a master regulator of transcription, translation, and RNA splicing. FUBP1 has been identified as a potent pro-proliferative and anti-apoptotic factor by modulation of complex networks. FUBP1 is also described either as an oncoprotein or a tumor suppressor. Especially, FUBP1 overexpression is observed in a growing number of cancer and leads to a deregulation of targets that includes the fine-tuned MYC oncogene. Moreover, recent loss-of-function analyses of FUBP1 establish its essential functions in hematopoietic stem cell maintenance and survival. Therefore, FUBP1 appears as an emerging suspect in hematologic disorders in addition to solid tumors. The scope of the present review is to describe the advances in our understanding of the molecular basis of FUBP1 functions in normal cells and carcinogenesis. We also delineate the recent progresses in the understanding of the master role of FUBP1 in normal and pathological hematopoiesis. We conclude that FUBP1 is not only worth studying biologically but is also of clinical relevance through its pivotal role in regulating multiple cellular processes and its involvement in oncogenesis.


P21 P53 FIR KH domain Leukemia c-KIT 



Acute lymphoblastic leukemia


Acute myeloid leukemia


AU-rich elements


Clear cell renal cell carcinoma


Chromatin immunoprecipitation


Chronic lymphocytic leukemia


Electrophoretic mobility shift assay


Enterovirus 71


Fluorescence activated cell sorting


Food and drug administration


Hepatocellular carcinoma


Hepatitis C virus


Hematopoietic stem cells


Internal ribosome entry site




Nuclear localization signal


Non-small cell lung cancer


Systematic evolution of ligands by exponential enrichment


Single nucleotide variation


Single-stranded DNA


Transcription start site



This work was supported by Ligue Régionale contre le cancer (comité 22, 35, 56, 79, 41) (MBT, LD), SFR Biosit UMS CNRS 3480—INSERM 018 (MBT), Région Bretagne (LD, MBT), The Société Française d’Hématologie (LD), Rennes Métropole (MBT), the société française de lutte contre les cancers et les leucémies de l’enfant et de l’adolescent and the Fédération Enfants et Santé (MBT), a private donator Mrs. M-Dominique Blanc-Bert (MBT), Cancéropole Grand Ouest (LD), and the CNRS, Université de Rennes 1 and the People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme (FP7/2007-2013) under REA grant agreement no. 291851 (MBT).

Compliance with ethical standards

Conflict of interest

The authors declare no competing financial interests.


  1. 1.
    Zhang J, Chen QM (2013) Far upstream element binding protein 1: a commander of transcription, translation and beyond. Oncogene 32:2907–2916Google Scholar
  2. 2.
    Avigan MI, Strober B, Levens D (1990) A far upstream element stimulates c-myc expression in undifferentiated leukemia cells. J Biol Chem 265:18538–18545Google Scholar
  3. 3.
    Duncan R, Bazar L, Michelotti G et al (1994) A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev 8:465–480. Google Scholar
  4. 4.
    Levens D (2008) How the c-myc promoter works and why it sometimes does not. JNCI Monogr 2008:41–43. Google Scholar
  5. 5.
    Liu J, Chung H-J, Vogt M et al (2011) JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress. EMBO J 30:846–858. Google Scholar
  6. 6.
    Malz M, Weber A, Singer S et al (2009) Overexpression of far upstream element binding proteins: a mechanism regulating proliferation and migration in liver cancer cells. Hepatology 50:1130–1139. Google Scholar
  7. 7.
    Malz M, Bovet M, Samarin J et al (2014) Overexpression of far upstream element (FUSE) binding protein (FBP)-interacting repressor (FIR) supports growth of hepatocellular carcinoma. Hepatology 60:1241–1250Google Scholar
  8. 8.
    Rabenhorst U, Beinoraviciute-Kellner R, Brezniceanu M-L et al (2009) Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth. Hepatology 50:1121–1129. Google Scholar
  9. 9.
    Baumgarten P, Harter PN, Tönjes M et al (2014) Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity: FUBP1 expression in human gliomas. Neuropathol Appl Neurobiol 40:205–216. Google Scholar
  10. 10.
    Duan J, Bao X, Ma X et al (2017) Upregulation of far upstream element-binding protein 1 (FUBP1) promotes tumor proliferation and tumorigenesis of clear cell renal cell carcinoma. PLoS One 12:e0169852. Google Scholar
  11. 11.
    Hauck S, Hiesinger K, Khageh Hosseini S et al (2016) Pyrazolo[1,5a]pyrimidines as a new class of FUSE binding protein 1 (FUBP1) inhibitors. Bioorg Med Chem 24:5717–5729. Google Scholar
  12. 12.
    Singer S, Malz M, Herpel E et al (2009) Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res 69:2234–2243. Google Scholar
  13. 13.
    Bettegowda C, Agrawal N, Jiao Y et al (2011) Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333:1453–1455. Google Scholar
  14. 14.
    Yang L, Zhu J, Zhang J et al (2016) Far upstream element-binding protein 1 (FUBP1) is a potential c-Myc regulator in esophageal squamous cell carcinoma (ESCC) and its expression promotes ESCC progression. Tumor Biol 37:4115–4126. Google Scholar
  15. 15.
    Ding Z, Liu X, Liu Y et al (2015) Expression of far upstream element (FUSE) binding protein 1 in human glioma is correlated with c-Myc and cell proliferation. Mol Carcinog 54:405–415. Google Scholar
  16. 16.
    Rabenhorst U, Thalheimer FB, Gerlach K et al (2015) Single-stranded DNA-binding transcriptional regulator FUBP1 is essential for fetal and adult hematopoietic stem cell self-renewal. Cell Rep 11:1847–1855. Google Scholar
  17. 17.
    Zhou W, Chung Y-J, Castellar ER et al (2016) Far upstream element binding protein plays a crucial role in embryonic development, hematopoiesis, and stabilizing MYC expression levels. Am J Pathol. Google Scholar
  18. 18.
    Duncan R, Collins I, Tomonaga T et al (1996) A unique transactivation sequence motif is found in the carboxyl-terminal domain of the single-strand-binding protein FBP. Mol Cell Biol 16:2274–2282Google Scholar
  19. 19.
    Davis-Smyth T, Duncan RC, Zheng T et al (1996) The far upstream element-binding proteins comprise an ancient family of single-strand DNA-binding transactivators. J Biol Chem 271:31679–31687. Google Scholar
  20. 20.
    Chung H-J, Liu J, Dundr M et al (2006) FBPs are calibrated molecular tools to adjust gene expression. Mol Cell Biol 26:6584–6597. Google Scholar
  21. 21.
    Briata P, Bordo D, Puppo M et al (2016) Diverse roles of the nucleic acid-binding protein KHSRP in cell differentiation and disease. Wiley Interdiscip Rev RNA 7:227–240. Google Scholar
  22. 22.
    Gherzi R, Lee K-Y, Briata P et al (2004) A KH domain RNA binding protein, KSRP, promotes ARE-directed mRNA turnover by recruiting the degradation machinery. Mol Cell 14:571–583. Google Scholar
  23. 23.
    Gau B-H, Chen T-M, Shih Y-HJ, Sun HS (2011) FUBP3 interacts with FGF9 3′ microsatellite and positively regulates FGF9 translation. Nucleic Acids Res 39:3582–3593. Google Scholar
  24. 24.
    Weber A, Kristiansen I, Johannsen M et al (2008) The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer. BMC Cancer 8:369. Google Scholar
  25. 25.
    Zerbino DR, Achuthan P, Akanni W et al (2018) Ensembl 2018. Nucleic Acids Res 46:D754–D761. Google Scholar
  26. 26.
    Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D (1997) GeneCards: integrating information about genes, proteins and diseases. Trends Genet TIG 13:163Google Scholar
  27. 27.
    Valverde R, Edwards L, Regan L (2008) Structure and function of KH domains: structure and function of KH domains. FEBS J 275:2712–2726. Google Scholar
  28. 28.
    Chien H-L, Liao C-L, Lin Y-L (2011) FUSE binding protein 1 interacts with untranslated regions of japanese encephalitis virus RNA and negatively regulates viral replication. J Virol 85:4698–4706. Google Scholar
  29. 29.
    Tang Q, Xia W, Ji Q et al (2014) Role of far upstream element binding protein 1 in colonic epithelial disruption during dextran sulphate sodium-induced murine colitis. Int J Clin Exp Pathol 7:2019–2031Google Scholar
  30. 30.
    Jang M, Park BC, Kang S et al (2009) Far upstream element-binding protein-1, a novel caspase substrate, acts as a cross-talker between apoptosis and the c-myc oncogene. Oncogene 28:1529–1536Google Scholar
  31. 31.
    Kim MJ, Park B-J, Kang Y-S et al (2003) Downregulation of FUSE-binding protein and c-myc by tRNA synthetase cofactor p38 is required for lung cell differentiation. Nat Genet 34:330–336. Google Scholar
  32. 32.
    Atanassov BS, Dent SYR (2011) USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1. EMBO Rep 12:924–930. Google Scholar
  33. 33.
    Hornbeck PV, Zhang B, Murray B et al (2015) PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res 43:D512–D520. Google Scholar
  34. 34.
    Venturutti L, Cordo Russo RI, Rivas MA et al (2016) MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1. Oncogene 35:6189–6202. Google Scholar
  35. 35.
    Zhao D, Zhang Y, Song L (2017) MiR-16-1 targeted silences far upstream element binding protein 1 to advance the chemosensitivity to adriamycin in gastric cancer. Pathol Oncol Res POR. Google Scholar
  36. 36.
    Marceau AH (2012) Functions of single-strand DNA-binding proteins in DNA replication, recombination, and repair. Methods Mol Biol Clifton NJ 922:1–21. Google Scholar
  37. 37.
    Michelotti GA, Michelotti EF, Pullner A et al (1996) Multiple single-stranded cis elements are associated with activated chromatin of the human c-myc gene in vivo. Mol Cell Biol 16:2656–2669Google Scholar
  38. 38.
    Michelotti EF, Michelotti GA, Aronsohn AI, Levens D (1996) Heterogeneous nuclear ribonucleoprotein K is a transcription factor. Mol Cell Biol 16:2350–2360Google Scholar
  39. 39.
    Tomonaga T, Levens D (1996) Activating transcription from single stranded DNA. Proc Natl Acad Sci USA 93:5830–5835Google Scholar
  40. 40.
    Braddock DT (2002) Molecular basis of sequence-specific single-stranded DNA recognition by KH domains: solution structure of a complex between hnRNP K KH3 and single-stranded DNA. EMBO J 21:3476–3485. Google Scholar
  41. 41.
    Braddock DT, Louis JM, Baber JL et al (2002) Structure and dynamics of KH domains from FBP bound to single-stranded DNA. Nature 415:1051–1056. Google Scholar
  42. 42.
    Hsiao H, Nath A, Lin C-Y et al (2010) Quantitative characterization of the interactions among c-myc transcriptional regulators FUSE, FBP, and FIR. Biochemistry (Mosc) 49:4620–4634. Google Scholar
  43. 43.
    Benjamin LR, Chung H-J, Sanford S et al (2008) Hierarchical mechanisms build the DNA-binding specificity of FUSE binding protein. Proc Natl Acad Sci 105:18296–18301Google Scholar
  44. 44.
    Debaize L, Jakobczyk H, Avner S et al (2018) Interplay between transcription regulators RUNX1 and FUBP1 activates an enhancer of the oncogene c-KIT and amplifies cell proliferation. Nucleic Acids Res. Google Scholar
  45. 45.
    Stine ZE, Walton ZE, Altman BJ et al (2015) MYC, metabolism, and cancer. Cancer Discov 5:1024–1039. Google Scholar
  46. 46.
    Dang CV (2012) MYC on the Path to Cancer. Cell 149:22–35. Google Scholar
  47. 47.
    He L, Liu J, Collins I et al (2000) Loss of FBP function arrests cellular proliferation and extinguishes c-myc expression. EMBO J 19:1034–1044. Google Scholar
  48. 48.
    Feaver WJ, Svejstrup JQ, Bardwell L et al (1993) Dual roles of a multiprotein complex from S. cerevisiae in transcription and DNA repair. Cell 75:1379–1387. Google Scholar
  49. 49.
    Schaeffer L, Roy R, Humbert S et al (1993) DNA repair helicase: a component of BTF2 (TFIIH) basic transcription factor. Science 260:58–63. Google Scholar
  50. 50.
    Compe E, Egly J-M (2012) TFIIH: when transcription met DNA repair. Nat Rev Mol Cell Biol 13:343. Google Scholar
  51. 51.
    Parvin JD, Sharp PA (1993) DNA topology and a minimal set of basal factors for transcription by RNA polymerase II. Cell 73:533–540Google Scholar
  52. 52.
    Goodrich JA, Tjian R (1994) Transcription factors IIE and IIH and ATP hydrolysis direct promoter clearance by RNA polymerase II. Cell 77:145–156Google Scholar
  53. 53.
    Felsher DW, Bishop JM (1999) Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci USA 96:3940–3944Google Scholar
  54. 54.
    Liu J, He L, Collins I et al (2000) The FBP interacting repressor targets TFIIH to inhibit activated transcription. Mol Cell 5:331–341. Google Scholar
  55. 55.
    Liu J, Kouzine F, Nie Z et al (2006) The FUSE/FBP/FIR/TFIIH system is a molecular machine programming a pulse of c-myc expression. EMBO J 25:2119–2130. Google Scholar
  56. 56.
    Matsushita K, Tomonaga T, Shimada H et al (2006) An essential role of alternative splicing of c-myc suppressor FUSE-binding protein-interacting repressor in carcinogenesis. Cancer Res 66:1409–1417. Google Scholar
  57. 57.
    Crichlow GV, Zhou H, Hsiao H et al (2008) Dimerization of FIR upon FUSE DNA binding suggests a mechanism of c-myc inhibition. EMBO J 27:277–289. Google Scholar
  58. 58.
    Weber A, Liu J, Collins I, Levens D (2005) TFIIH operates through an expanded proximal promoter to fine-tune c-myc expression. Mol Cell Biol 25:147–161. Google Scholar
  59. 59.
    Rubin CI, Atweh GF (2004) The role of stathmin in the regulation of the cell cycle. J Cell Biochem 93:242–250. Google Scholar
  60. 60.
    Mistry SJ, Atweh GF (2002) Role of stathmin in the regulation of the mitotic spindle: potential applications in cancer therapy. Mt Sinai J Med N Y 69:299–304Google Scholar
  61. 61.
    Belletti B, Nicoloso MS, Schiappacassi M et al (2008) Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. Mol Biol Cell 19:2003–2013. Google Scholar
  62. 62.
    Kuner R, Muley T, Meister M et al (2009) Global gene expression analysis reveals specific patterns of cell junctions in non-small cell lung cancer subtypes. Lung Cancer Amst Neth 63:32–38. Google Scholar
  63. 63.
    Krumlauf R (1994) Hox genes in vertebrate development. Cell 78:191–201Google Scholar
  64. 64.
    Lawrence HJ, Sauvageau G, Humphries RK, Largman C (1996) The role of HOX homeobox genes in normal and leukemic hematopoiesis. Stem Cells Dayt Ohio 14:281–291. Google Scholar
  65. 65.
    Broudy VC (1997) Stem cell factor and hematopoiesis. Blood 90:1345–1364Google Scholar
  66. 66.
    Kitamura Y, Hirotab S (2004) Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci CMLS 61:2924–2931. Google Scholar
  67. 67.
    Gartel AL, Serfas MS, Tyner AL (1996) p21–negative regulator of the cell cycle. Proc Soc Exp Biol Med 213:138–149Google Scholar
  68. 68.
    Gartel AL, Tyner AL (2002) The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1:639–649Google Scholar
  69. 69.
    Soria G, Speroni J, Podhajcer OL et al (2008) p21 differentially regulates DNA replication and DNA-repair-associated processes after UV irradiation. J Cell Sci 121:3271–3282. Google Scholar
  70. 70.
    Dixit U, Liu Z, Pandey AK et al (2014) Fuse binding protein antagonizes the transcription activity of tumor suppressor protein. BMC Cancer. Google Scholar
  71. 71.
    Dixit U, Pandey AK, Liu Z et al (2015) FUSE binding protein 1 facilitates persistent hepatitis C virus replication in hepatoma cells by regulating tumor suppressor p53. J Virol 89:7905–7921. Google Scholar
  72. 72.
    Frost JR, Mendez M, Soriano AM (2018) Adenovirus 5 E1A-mediated suppression of p53 via FUBP1. J Virol. Google Scholar
  73. 73.
    Sully G, Dean JLE, Wait R et al (2004) Structural and functional dissection of a conserved destabilizing element of cyclo-oxygenase-2 mRNA: evidence against the involvement of AUF-1 [AU-rich element/poly(U)-binding/degradation factor-1], AUF-2, tristetraprolin, HuR (Hu antigen R) or FBP1 (far-upstream-sequence-element-binding protein 1). Biochem J 377:629–639. Google Scholar
  74. 74.
    Zhang Z, Harris D, Pandey VN (2008) The FUSE binding protein is a cellular factor required for efficient replication of hepatitis C virus. J Virol 82:5761–5773. Google Scholar
  75. 75.
    Caput D, Beutler B, Hartog K et al (1986) Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA 83:1670–1674Google Scholar
  76. 76.
    Zhang T, Kruys V, Huez G, Gueydan C (2002) AU-rich element-mediated translational control: complexity and multiple activities of trans-activating factors. Biochem Soc Trans 30:952–958. Google Scholar
  77. 77.
    Roberto Gherzi, Ching-Yi Chen, Michele Trabucchi et al (2010) The role of KSRP in mRNA decay and microRNA precursor maturation. Wiley Interdiscip Rev RNA 1:230–239. Google Scholar
  78. 78.
    Jacob AG, Singh RK, Mohammad F et al (2014) The splicing factor FUBP1 is required for the efficient splicing of oncogene MDM2 Pre-mRNA. J Biol Chem 289:17350–17364. Google Scholar
  79. 79.
    Miro J, Laaref AM, Rofidal V et al (2015) FUBP1: a new protagonist in splicing regulation of the DMD gene. Nucleic Acids Res 43:2378–2389. Google Scholar
  80. 80.
    Zheng W, Shen F, Hu R et al (2016) Far upstream element-binding protein 1 binds the 3′ untranslated region of PKD2 and suppresses its translation. J Am Soc Nephrol. Google Scholar
  81. 81.
    Irwin N, Baekelandt V, Goritchenko L, Benowitz LI (1997) Identification of two proteins that bind to a pyrimidine-rich sequence in the 3′-untranslated region of GAP-43 mRNA. Nucleic Acids Res 25:1281–1288Google Scholar
  82. 82.
    Olanich ME, Moss BL, Piwnica-Worms D et al (2011) Identification of FUSE-binding protein 1 as a regulatory mRNA-binding protein that represses nucleophosmin translation. Oncogene 30:77–86Google Scholar
  83. 83.
    Box JK, Paquet N, Adams MN et al (2016) Nucleophosmin: from structure and function to disease development. BMC Mol Biol. Google Scholar
  84. 84.
    Williams BY, Hamilton SL, Sarkar HK (2000) The survival motor neuron protein interacts with the transactivator FUSE binding protein from human fetal brain. FEBS Lett 470:207–210. Google Scholar
  85. 85.
    Zheng Y, Miskimins WK (2011) Far upstream element binding protein 1 activates translation of p27Kip1 mRNA through its internal ribosomal entry site. Int J Biochem Cell Biol 43:1641–1648. Google Scholar
  86. 86.
    Huang P-N, Lin J-Y, Locker N et al (2011) Far upstream element binding protein 1 binds the internal ribosomal entry site of enterovirus 71 and enhances viral translation and viral growth. Nucleic Acids Res 39:9633–9648. Google Scholar
  87. 87.
    Tsai F-J, Lin C-W, Lai C-C et al (2011) Kaempferol inhibits enterovirus 71 replication and internal ribosome entry site (IRES) activity through FUBP and HNRP proteins. Food Chem 128:312–322. Google Scholar
  88. 88.
    Hung C-T, Kung Y-A, Li M-L et al (2016) Additive promotion of viral internal ribosome entry site-mediated translation by far upstream element-binding protein 1 and an enterovirus 71-induced cleavage product. PLoS Pathog. Google Scholar
  89. 89.
    Lin J-Y, Li M-L, Shih S-R (2009) Far upstream element binding protein 2 interacts with enterovirus 71 internal ribosomal entry site and negatively regulates viral translation. Nucleic Acids Res 37:47–59. Google Scholar
  90. 90.
    Min H, Turck CW, Nikolic JM, Black DL (1997) A new regulatory protein, KSRP, mediates exon inclusion through an intronic splicing enhancer. Genes Dev 11:1023–1036Google Scholar
  91. 91.
    Labourier E, Adams MD, Rio DC (2001) Modulation of P-Element Pre-mRNA Splicing by a Direct Interaction between PSI and U1 snRNP 70 K Protein. Mol Cell 8:363–373. Google Scholar
  92. 92.
    Rappsilber J, Ryder U, Lamond AI, Mann M (2002) Large-Scale proteomic analysis of the human spliceosome. Genome Res 12:1231–1245. Google Scholar
  93. 93.
    Pan Q, Shai O, Lee LJ et al (2008) Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 40:1413–1415. Google Scholar
  94. 94.
    Li H, Wang Z, Zhou X et al (2013) Far upstream element-binding protein 1 and RNA secondary structure both mediate second-step splicing repression. Proc Natl Acad Sci 110:E2687–E2695. Google Scholar
  95. 95.
    Will CL, Lührmann R (2011) Spliceosome structure and function. Cold Spring Harb Perspect Biol. Google Scholar
  96. 96.
    Wang J, Schultz PG, Johnson KA (2018) Mechanistic studies of a small-molecule modulator of SMN2 splicing. Proc Natl Acad Sci USA 115:E4604–E4612. Google Scholar
  97. 97.
    Freedman DA, Wu L, Levine AJ (1999) Functions of the MDM2 oncoprotein. Cell Mol Life Sci CMLS 55:96–107. Google Scholar
  98. 98.
    Emery AEH (2002) The muscular dystrophies. Lancet Lond Engl 359:687–695. Google Scholar
  99. 99.
    Sutandy FXR, Ebersberger S, Huang L et al (2018) In vitro iCLIP-based modeling uncovers how the splicing factor U2AF2 relies on regulation by cofactors. Genome Res 28:699–713. Google Scholar
  100. 100.
    Hwang I, Cao D, Na Y et al (2018) Far upstream element-binding protein 1 regulates LSD1 alternative splicing to promote terminal differentiation of neural progenitors. Stem Cell Rep. Google Scholar
  101. 101.
    Ostrom QT, Bauchet L, Davis FG et al (2014) The epidemiology of glioma in adults: a “state of the science” review. Neuro-Oncol 16:896–913. Google Scholar
  102. 102.
    Barbashina V, Salazar P, Holland EC et al (2005) Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res Off J Am Assoc Cancer Res 11:1119–1128Google Scholar
  103. 103.
    Sahm F, Koelsche C, Meyer J et al (2012) CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol (Berl) 123:853–860. Google Scholar
  104. 104.
    Chan AK-Y, Pang JC-S, Chung NY-F et al (2014) Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. Mod Pathol Off J US Can Acad Pathol Inc 27:332–342. Google Scholar
  105. 105.
    Brat DJ, Verhaak RGW, Cancer Genome Atlas Research Network et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498. Google Scholar
  106. 106.
    Suzuki H, Aoki K, Chiba K et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458–468. Google Scholar
  107. 107.
    Aihara K, Nagae G (2017) Genetic and epigenetic stability of oligodendrogliomas at recurrence. Acta Neuropathol Commun. Google Scholar
  108. 108.
    Bailey MH, Tokheim C, Porta-Pardo E et al (2018) Comprehensive characterization of cancer driver genes and mutations. Cell 173:371–385. Google Scholar
  109. 109.
    Yip S, Butterfield YS, Morozova O et al (2012) Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 226:7–16. Google Scholar
  110. 110.
    Chen J, Hackett CS, Zhang S et al (2015) The genetics of splicing in neuroblastoma. Cancer Discov 5:380–395. Google Scholar
  111. 111.
    Bradley RK, Merkin J, Lambert NJ, Burge CB (2012) Alternative splicing of RNA triplets is often regulated and accelerates proteome evolution. PLoS Biol 10:e1001229. Google Scholar
  112. 112.
    Bartel F, Taubert H, Harris LC (2002) Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2:9–15. Google Scholar
  113. 113.
    Singh RK, Tapia-Santos A, Bebee TW, Chandler DS (2009) Conserved sequences in the final intron of MDM2 are essential for the regulation of alternative splicing of MDM2 in response to stress. Exp Cell Res 315:3419–3432. Google Scholar
  114. 114.
    Steinman HA, Burstein E, Lengner C et al (2004) An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. J Biol Chem 279:4877–4886. Google Scholar
  115. 115.
    Seiler M, Peng S, Agrawal AA et al (2018) Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep 23:282–296. Google Scholar
  116. 116.
    Liu Z-H, Hu J-L, Liang J-Z et al (2015) Far upstream element-binding protein 1 is a prognostic biomarker and promotes nasopharyngeal carcinoma progression. Cell Death Dis 6:e1920. Google Scholar
  117. 117.
    Pénzváltó Z, Lánczky A, Lénárt J et al (2014) MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer. BMC Cancer 14:837. Google Scholar
  118. 118.
    Zhang J, Xiong X, Hua X et al (2017) Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin. Oncol Lett 14:5819–5824. Google Scholar
  119. 119.
    Yu MC, Yuan J-M, Lu SC (2008) Alcohol, cofactors and the genetics of hepatocellular carcinoma. J Gastroenterol Hepatol 23:S92–S97. Google Scholar
  120. 120.
    Sanyal AJ, Yoon SK, Lencioni R (2010) The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 15:14–22. Google Scholar
  121. 121.
    Kawate S, Fukusato T, Ohwada S et al (1999) Amplification of c-myc in hepatocellular carcinoma: correlation with clinicopathologic features, proliferative activity and p53 overexpression. Oncology 57:157–163. Google Scholar
  122. 122.
    El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576. Google Scholar
  123. 123.
    Murakami H, Sanderson ND, Nagy P et al (1993) Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res 53:1719–1723Google Scholar
  124. 124.
    Zimonjic DB, Keck CL, Thorgeirsson SS, Popescu NC (1999) Novel recurrent genetic imbalances in human hepatocellular carcinoma cell lines identified by comparative genomic hybridization. Hepatol Baltimore, MD 29:1208–1214. Google Scholar
  125. 125.
    Schlaeger C, Longerich T, Schiller C et al (2008) Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatol Baltimore, MD 47:511–520. Google Scholar
  126. 126.
    Zubaidah RM, Tan GS, Tan SBE et al (2008) 2-D DIGE profiling of hepatocellular carcinoma tissues identified isoforms of far upstream binding protein (FUBP) as novel candidates in liver carcinogenesis. Proteomics 8:5086–5096. Google Scholar
  127. 127.
    Wen H, Ma H, Li P et al (2017) Expression of far upstream element-binding protein 1 correlates with c-Myc expression in sacral chordomas and is associated with tumor progression and poor prognosis. Biochem Biophys Res Commun 491:1047–1054. Google Scholar
  128. 128.
    Xiong X, Zhang J, Liang W et al (2016) Fuse-binding protein 1 is a target of the EZH2 inhibitor GSK343, in osteosarcoma cells. Int J Oncol 49:623–628Google Scholar
  129. 129.
    Bièche I, Lachkar S, Becette V et al (1998) Overexpression of the stathmin gene in a subset of human breast cancer. Br J Cancer 78:701–709Google Scholar
  130. 130.
    Müller B, Bovet M, Yin Y et al (2015) Concomitant expression of far upstream element (FUSE) binding protein (FBP) interacting repressor (FIR) and its splice variants induce migration and invasion of non-small cell lung cancer (NSCLC) cells. J Pathol 237:390–401. Google Scholar
  131. 131.
    Brisbin AG, Asmann YW, Song H et al (2011) Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development. BMC Med Genet 12:156. Google Scholar
  132. 132.
    Boelens MC, Kok K, van der Vlies P et al (2009) Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis. Lung Cancer Amsterdam Netherlands 66:372–378. Google Scholar
  133. 133.
    Moinzadeh P, Breuhahn K, Stützer H, Schirmacher P (2005) Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade—results of an explorative CGH meta-analysis. Br J Cancer 92:935–941. Google Scholar
  134. 134.
    Matsushita K, Tomonaga T, Kajiwara T et al (2009) c-myc suppressor FBP-interacting repressor for cancer diagnosis and therapy. Front Biosci Landmark Ed 14:3401–3408Google Scholar
  135. 135.
    Saito I, Miyamura T, Ohbayashi A et al (1990) Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci 87:6547–6549Google Scholar
  136. 136.
    Shi ST, Lai MM (2001) Hepatitis C viral RNA: challenges and promises. Cell Mol Life Sci CMLS 58:1276–1295. Google Scholar
  137. 137.
    Wesely J, Steiner M, Schntgen F et al (2017) Delayed mesoderm and erythroid differentiation of murine embryonic stem cells in the absence of the transcriptional regulator FUBP1. Stem Cells Int 2017:1–12. Google Scholar
  138. 138.
    Wilson A, Murphy MJ, Oskarsson T et al (2004) c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev 18:2747–2763. Google Scholar
  139. 139.
    Reavie L, Gatta GD, Crusio K et al (2010) Hematopoietic stem cell differentiation regulated by a single ubiquitin ligase: substrate complex. Nat Immunol 11:207–215. Google Scholar
  140. 140.
    Hoffman B, Amanullah A, Shafarenko M, Liebermann DA (2002) The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 21:3414–3421. Google Scholar
  141. 141.
    Freytag SO (1988) Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1. Mol Cell Biol 8:1614–1624Google Scholar
  142. 142.
    Hoffman B, Liebermann DA, Selvakumaran M, Nguyen HQ (1996) Role of c-myc in myeloid differentiation, growth arrest and apoptosis. Curr Top Microbiol Immunol 211:17–27Google Scholar
  143. 143.
    Eppert K, Takenaka K, Lechman ER et al (2011) Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 17:1086–1093. Google Scholar
  144. 144.
    Delgado MD, León J (2010) Myc roles in hematopoiesis and leukemia. Genes Cancer. Google Scholar
  145. 145.
    Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R (2005) Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells 23:16–43. Google Scholar
  146. 146.
    Weidemann RR, Behrendt R, Schoedel KB et al (2017) Constitutive Kit activity triggers B-cell acute lymphoblastic leukemia-like disease in mice. Exp Hematol 45:45–55. Google Scholar
  147. 147.
    Landau DA, Tausch E, Taylor-Weiner AN et al (2015) Mutations driving CLL and their evolution in progression and relapse. Nature 526:525–530. Google Scholar
  148. 148.
    Lindqvist CM, Lundmark A, Nordlund J et al (2016) Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes. Oncotarget 27:64071–64088. Google Scholar
  149. 149.
    Klener P, Fronkova E, Berkova A et al (2016) Mantle cell lymphoma-variant Richter syndrome: detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years: mantle cell lymphoma-variant Richter syndrome. Int J Cancer 139:2252–2260. Google Scholar
  150. 150.
    Huth JR, Yu L, Collins I et al (2004) NMR-driven discovery of benzoylanthranilic acid inhibitors of far upstream element binding protein binding to the human oncogene c-myc promoter. J Med Chem 47:4851–4857. Google Scholar
  151. 151.
    Au SL-K, Wong CC-L, Lee JM-F et al (2013) EZH2-mediated H3K27me3 is involved in epigenetic repression of deleted in liver cancer 1 in human cancers. PLoS One 8:e68226. Google Scholar
  152. 152.
    Lv Y-F, Yan G-N, Meng G (2015) Enhancer of zeste homolog two silencing inhibits tumor growth and lung metastasis in osteosarcoma. Sci Rep. Google Scholar
  153. 153.
    Niforou KM, Anagnostopoulos AK, Vougas K et al (2008) The proteome profile of the human osteosarcoma U2OS cell line. Cancer Genom Proteom 5:63–78Google Scholar
  154. 154.
    Varambally S, Dhanasekaran SM, Zhou M et al (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–629. Google Scholar
  155. 155.
    Kleer CG, Cao Q, Varambally S et al (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100:11606–11611. Google Scholar
  156. 156.
    Khageh Hosseini S, Kolterer S, Steiner M et al (2017) Camptothecin and its analog SN-38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE. Biochem Pharmacol 146:53–62. Google Scholar
  157. 157.
    Zhou X, Edmonson MN, Wilkinson MR et al (2016) Exploring genomic alteration in pediatric cancer using protein paint. Nat Genet 48:4–6. Google Scholar
  158. 158.
    Barretina J, Caponigro G, Stransky N et al (2012) The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603–607. Google Scholar
  159. 159.
    Idbaih A, Ducray F, Dehais C et al (2012) SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas. PLoS One 7:e45950. Google Scholar
  160. 160.
    Cahill DP, Louis DN, Cairncross JG (2015) Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. CNS Oncol 4:287–294. Google Scholar
  161. 161.
    Erdem-Eraslan L, Heijsman D, de Wit M et al (2015) Tumor-specific mutations in low-frequency genes affect their functional properties. J Neurooncol 122:461–470. Google Scholar
  162. 162.
    Zhang L, Liu Y, Wang M (2017) EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients. J Mol Cell Biol. Google Scholar
  163. 163.
    Ma J, Chen M, Xia S-K et al (2013) Prostaglandin E2 promotes liver cancer cell growth by the upregulation of FUSE-binding protein 1 expression. Int J Oncol 42:1093–1104Google Scholar
  164. 164.
    Samarin J, Laketa V, Malz M et al (2016) PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells. Hepatology 63:813–826. Google Scholar
  165. 165.
    Zhang F, Tian Q, Wang Y (2013) Far upstream element-binding protein 1 (FUBP1) is overexpressed in human gastric cancer tissue compared to non-cancerous tissue. Onkologie 36:650–655. Google Scholar
  166. 166.
    Jia MY, Wang YJ (2014) Far upstream element-binding protein 1(FUBP1) expression differs between human colorectal cancer and non-cancerous tissue. Neoplasma 61:533–540. Google Scholar
  167. 167.
    Gagné J-P, Gagné P, Hunter JM et al (2005) Proteome profiling of human epithelial ovarian cancer cell line TOV-112D. Mol Cell Biochem 275:25–55Google Scholar
  168. 168.
    Zhong Q, Liu Z, Lin Z-R et al (2017) The RARS-MADlLl fusion gene induces cancer stem cell-like properties and therapeutic resistance in nasopharyngeal carcinoma. Clin Cancer Res. Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes)-UMR 6290RennesFrance
  2. 2.Univ Brest, INSERM, EFS, UMR 1078, GGBBrestFrance
  3. 3.CHRU de Brest, laboratoire de cytogénétiqueBrestFrance

Personalised recommendations